Nalaganje...
Response rates for hip, femoral neck, and lumbar spine bone mineral density in patients treated with abaloparatide followed by alendronate: Results from phase 3 ACTIVExtend
Abaloparatide is a selective activator of the parathyroid hormone type 1 receptor signaling pathway that favors the stimulation of bone formation. Here, we report a prospective, exploratory analysis of bone mineral density (BMD) response rates comparing sequential abaloparatide/alendronate vs placeb...
Shranjeno v:
| izdano v: | Bone Rep |
|---|---|
| Main Authors: | , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Elsevier
2019
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6883300/ https://ncbi.nlm.nih.gov/pubmed/31799340 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bonr.2019.100230 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|